RJT
RMD icon

Raymond James Trust’s ResMed RMD Stock Holding History

Raymond James Trust’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$346K Buy
1,419
+1
+0.1% +$223 0.01% 965
2024
Q2 		$271K Sell
1,418
-2
-0.1% -$406 0.01% 1027
2024
Q1 		$281K Buy
1,420
+2
+0.1% +$366 0.01% 1010
2023
Q4 		$244K Buy
1,418
+42
+3% +$6.45K 0.01% 1045
2023
Q3 		$203K Sell
1,376
-64
-4% -$11.6K 0.01% 1080
2023
Q2 		$315K Buy
1,440
+19
+1% +$4.24K 0.01% 868
2023
Q1 		$311K Buy
1,421
+54
+4% +$11.7K 0.01% 853
2022
Q4 		$285K Buy
1,367
+6
+0.4% +$1.32K 0.01% 854
2022
Q3 		$297K Buy
1,361
+20
+1% +$4.55K 0.01% 794
2022
Q2 		$281K Sell
1,341
-24
-2% -$5.11K 0.01% 834
2022
Q1 		$331K Sell
1,365
-14
-1% -$3.39K 0.01% 829
2021
Q4 		$359K Buy
1,379
+32
+2% +$8.3K 0.01% 795
2021
Q3 		$355K Sell
1,347
-8
-0.6% -$2.19K 0.01% 770
2021
Q2 		$334K Sell
1,355
-1
-0.1% -$210 0.01% 810
2021
Q1 		$263K Buy
+1,356
New +$272K 0.01% 889

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Raymond James Trust's RMD Position: Q3 2024 in Review

Raymond James Trust increased its ResMed (RMD) stake by 0.07% in Q3 2024, buying an estimated $223 and bringing the position to 1,419 shares worth $346K. The position accounts for 0.01% of the portfolio, ranked #965.

Raymond James Trust first reported a position in RMD in Q1 2021 and has held it in 15 quarters since. The position peaked at $359K in Q4 2021. 801 funds tracked by Wall St. Rank hold RMD as of Q3 2024.

  • Raymond James Trust held 1,419 shares of ResMed worth $346K as of Q3 2024.
  • Raymond James Trust bought 1 ResMed share in Q3 2024, an estimated $223.
  • ResMed made up 0.01% of Raymond James Trust's portfolio in Q3 2024, its #965 holding.
  • Raymond James Trust first reported a position in ResMed in Q1 2021 and has held it in 15 quarters since.
  • Raymond James Trust's ResMed position peaked at $359K in Q4 2021.
  • 801 funds tracked by Wall St. Rank held ResMed as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.